Nguyen M H, Yu C Y
Department of Medicine, University of Florida College of Medicine, Gainesville 32610, USA.
J Antimicrob Chemother. 1998 Aug;42(2):253-6. doi: 10.1093/jac/42.2.253.
We compared the in-vitro activity of fluconazole, itraconazole, ketoconazole and voriconazole against 67 blood isolates of Candida spp. exhibiting a wide range of fluconazole MICs (0.125 to >64 mg/L). Voriconazole was the most potent in vitro, followed by itraconazole, ketoconazole and fluconazole. Itraconazole and voriconazole had in-vitro activity against fluconazole-susceptible and -resistant candida isolates. Higher itraconazole and voriconazole MICs were observed in isolates exhibiting higher fluconazole MICs, suggesting cross-resistance. Itraconazole and voriconazole MICs of > or =16 mg/L were observed only in Candida albicans and Candida tropicalis. Candida krusei and Candida glabrata exhibited itraconazole MICs of 0.5-1 mg/L and voriconazole MICs of 0.25-0.5 mg/L.
我们比较了氟康唑、伊曲康唑、酮康唑和伏立康唑对67株念珠菌属血液分离株的体外活性,这些分离株呈现出广泛的氟康唑最低抑菌浓度(MICs)(0.125至>64mg/L)。伏立康唑在体外活性最强,其次是伊曲康唑、酮康唑和氟康唑。伊曲康唑和伏立康唑对氟康唑敏感和耐药的念珠菌分离株均有体外活性。在氟康唑MICs较高的分离株中观察到较高的伊曲康唑和伏立康唑MICs,提示存在交叉耐药。仅在白色念珠菌和热带念珠菌中观察到伊曲康唑和伏立康唑的MICs≥16mg/L。克柔念珠菌和光滑念珠菌的伊曲康唑MICs为0.5 - 1mg/L,伏立康唑MICs为0.25 - 0.5mg/L。